Shots :
- Sandoz has introduced Tyruko (natalizumab), biosimilar of Tysabri for the treatment of r/r multiple sclerosis (RRMS), in Germany which will be available from Feb 1
- Polpharma Biologics is responsible for the development, manufacturing and supply of Tyruko while Sandoz holds its commercialization rights in all markets as per a global commercialization agreement signed between them in 2019
- Tyruko is an anti-α4 integrin mAb indicated as a single disease-modifying therapy (DMT) for treating adults with highly active RRMS
Ref: Sandoz| Image: Sandoz| Press Release
Related News:- Alvotech Reports Data from the Trial of AVT03 (Biosimilar, Prolia and Xgeva) for Skeletal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
